WebOct 1, 2016 · Background Paclitaxel-based regimens are frequently associated with the development of peripheral neuropathy. The autonomous nervous system (ANS) effects, however, of this chemotherapeutic agent remain unexplored. Methods We investigated a group of 31 female patients with ovarian cancer receiving treatment with paclitaxel and … WebConclusion: Concurrent chemoradiotherapy with nab-paclitaxel 40 mg/m (2) and carboplatin AUC 2 is a safe and well-tolerated therapeutic regimen in patients with …
Design and Characterization of Carboplatin and Paclitaxel …
WebObjective: To evaluate the adverse affects of paclitaxel and carboplatin combination chemotherapy. Design: Descriptive cross sectional study Material and method: Patients … WebApr 12, 2024 · Participants with a PD-L1 CPS ≥ 10 will receive after randomization ociperlimab + tislelizumab + chemotherapy. The choice of one of three chemotherapy … data flurry com
Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in …
WebNov 20, 2024 · The Gynecologic Oncology Group studied carboplatin plus paclitaxel (TC) as a noninferior alternative to TAP. Methods: GOG0209 was a phase III, randomized, … WebMar 28, 2024 · Approximately two-thirds of patients with PDAC are diagnosed at a metastatic stage. 5 In this setting, the treatment relies on systemic chemotherapy, but options are limited. Following more than 15 years of use of gemcitabine alone as standard, the FOLFIRINOX (5-fluorouracil administered as leucovorin and 5-fluorouracil (LV5FU2), … Webtime points (<0.001) for both carboplatin plus paclitaxel P and cisplatin plus paclitaxel. Although the median was zero, there was a difference in the interquartile range. When examining the pairwise difference between the two time-points of the carboplatin plus paclitaxel regimen, all questionnaires achieved significantly worse scores between data flow vs data pipeline